M_2和β_1受体抗体与慢性肺源性心脏病关系的实验研究

目的用缺氧方法制备的肺源性心脏病(肺心病)大鼠为对象,研究肺心病中M2和β1受体抗体的含量及其与疾病的关系。方法选取健康雄性Wistar大鼠36只,随机分为3组:单纯缺氧组,缺氧加注射FeCl3组,健康对照组。SA-酶联免疫吸附测定(ELISA)法检测血清M2和β1受体抗体变化。最后处死大鼠观察心脏指标,并分析它与抗体滴度的相关性。结果血清中M2和β1受体抗体随缺氧时间延长而升高,滴度分别到第3周达高峰M2受体抗体为1∶80(单纯缺氧组)和1∶53(缺氧加注射FeCl3组),β1受体抗体为1∶60(单纯缺氧组)和1∶45(缺氧加注射FeCl3组),并且P/N值从第2周开始有阳性意义,到第3周同样达高峰M2和β1受体抗体分别为2.88(单纯缺氧组)、2.76(缺氧加注射FeCl3组)和3.25(单纯缺氧组)、3.99(缺氧加注射FeCl3组)。而肺心病大鼠心脏指标最终改变为R/(L+S)0.333±0.027(单纯缺氧组),0.348±0.033(缺氧加注射FeCl3组),R/BW×10-30.58±0.13(单纯缺氧组),0.60±0.15(缺氧加注射FeCl3组),(L+S)/BW×10-32.000±0.024(单纯缺氧组),2.081±0.037(缺氧加注射FeCl3组),并且抗体滴度与心脏改变呈正相关。结论M2和β1受体抗体阳性率及抗体滴度在大鼠肺心病模型中明显增高,表明肺心病的发生发展与M2和β1受体的自身抗体密切相关。     

A -243A-->G polymorphism upstream of the gene encoding GAD65 associates with lower levels of body mass index and glycaemia in a population-based sample of 5857 middle-aged White subjects.

AIMS: The glutamate decarboxylase gene (GAD2) encodes GAD65, an enzyme catalysing the production of the gamma-aminobutyric acid (GABA) which interacts with neuropeptide Y to stimulate food intake. It has been suggested that in pancreatic islets, GABA serves as a functional regulator of pancreatic hormone release. Conflicting results have been reported concerning the potential impact of GAD2 variation on estimates of energy metabolism. The aim of this study was to elucidate potential associations between the GAD2-243A-->G polymorphism and levels of body mass index (BMI) and estimates of glycaemia. METHODS: Using high-throughput chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, the GAD2-243A-->G (rs2236418) polymorphism was genotyped in a population-based sample (Inter99) of 5857 middle-aged, unrelated Danish White subjects. RESULTS: The G-allele was associated with modestly lower BMI (P = 0.01). In a case-control study of obesity, the G-allele frequency in 2582 participants with BMI < 25 kg/m2 was 19.5% (18.4-20.6) compared with 17.1% (15.5-18.8) in 968 participants having BMI > or = 30 kg/m2 (P = 0.03), odds ratio 0.9 (0.7-1.0). Of the 5857 subjects, GG carriers had lower fasting plasma glucose levels (mmol/l) [AA (n = 3859) 5.6 +/- 0.8; AG (n = 1792) 5.5 +/- 0.8; GG (n = 206) 5.5 +/- 0.8, P = 0.008] and lower 30-min oral glucose tolerance test (OGTT)-related plasma glucose levels (AA 8.7 +/- 1.9; AG 8.6 +/- 1.9; GG 8.6 +/- 2.0, P = 0.04), adjusted for sex, age and BMI. Analysing subjects who were both normoglycaemic and glucose tolerant (n = 4431) GG carriers still had lower fasting plasma glucose concentrations: AA (n = 2895) 5.3 +/- 0.4; AG (n = 1383) 5.3 +/- 0.4; GG (n = 153) 5.2 +/- 0.4 (P = 9.10(-5)). CONCLUSION: The present study suggests that the GAD2-243A-->G polymorphism in a population of middle-aged White people associates with a modest reduction in BMI and fasting and OGTT-related plasma glucose levels.     

Addition of Transdermal or Inhaled Long-Acting β 2-Agonists in Adult Asthmatic Patients Treated with Inhaled Corticosteroids: Switchover Study from Tulobuterol Patch to Salmeterol Dry Powder Inhaler

Sixty-four patients with persistent asthma receiving 200 to 800 μ g of fluticasone propionate daily were enrolled in this switchover study. The patients applied a tulobuterol patch 2 mg every 24 hours for 4 weeks followed by inhalation of salmeterol 100 μ g bid for 4 weeks. The mean values for morning and evening peak expiratory flow improved significantly compared with baseline during the 4 weeks of tulobuterol patch treatment. Further improvement was seen on switching to salmeterol treatment, which was significant even in the first week, and continued until the final week of the study. Use of salmeterol alone resulted in a significant increase in the percentage of forced expiratory volume in 1 second %FEV1 from baseline, with 51% of patients feeling that the treatment was effective (vs. 37% on tulobuterol). These data suggest that salmeterol can achieve better control in asthmatic patients after switching from using tulobuterol patches.     

重组骨形态发生蛋白-2结合软骨下钻孔治疗犬关节软骨全层缺损的实验研究

目的 研究重组骨形态发生蛋白-2(rhBMP-2)结合软骨下骨钻孔治疗犬关节软骨全层缺损的可行性，为临床应用提供实验依据。方法 依照软骨缺损处理方法的不同将64侧股骨髁随机均分为4组：①结合组：软骨下骨钻孔 胶原海绵吸附rhBMP-2充填软骨缺损；②BMP组：胶原海绵吸附rhBMP-2充填软骨缺损；③钻孔组：单纯软骨下骨钻孔；④对照组：不作处理或单纯用胶原海绵填塞。术后2、4、8、12周取材观察其大体、光镜、透射电镜、免疫组织化学情况。结果 除对照组仅有纤维组织修复外，其余3组均有不同程度的软骨修复，但结合组的修复在组织细胞形态、超微结构、Ⅱ型胶原含量等方面均明显优于其他两组。结论rhBMP-2结合软骨下骨钻孔能有效修复犬膝关节软骨的全层缺损，该技术可行，有望在临床应用。     

Risk factors of type 2 diabetes among Korean adults: The 2001 Korean national health and nutrition examination survey

This study aimed to identify risk factors for type 2 diabetes (T2D) in Korea, a rapidly changing country. Data of 5,132 adults aged 20-85 were used from the 2001 Korean Health and Nutrition Examination Survey. Multiple logistic regression was carried out to identify risk factors for T2D. Three models were specified: (i) socioeconomic and demographic factors (model 1: age, gender, education, poverty income ratio, employment), (ii) behavioral risk factors and covariates (model 2: obesity, physical activity, smoking, alcohol drinking, dietary quality, family history of T2D, co-morbidity) and (iii) socioeconomic, demographic, and behavioral factors (model 3). The prevalence of T2D was 7.4%. Less education (OR 1.41, 95% CI 1.08-1.84), age (OR 2.19, 95% CI 1.56-3.08 in 40-59 yrs, OR 4.05, 95% CI 2.76-5.95 in 60 yrs + comparing to 20-39 yrs) and abdominal obesity (OR 2.24, 95% CI 1.79-2.82) were risk factors for T2D even after controlling for other factors simultaneously. There was a significant association of T2D with ever smoking (OR 1.34, 95% CI 1.06-1.67). The relationship of age with T2D was modified by gender in model 1 and the relationship of smoking with T2D was modified by obesity in model 2. Less educated, older, obese or ever smokers were more likely to have T2D. Gender mediated the relationship of age, and obesity mediated the relationship of smoking, with T2D. Intervention programs for T2D in Korea should take the interactions among risk factors into account.     

2005～2007年我国非甾体抗炎药市场应用分析

目的：以骨骼肌肉系统使用非甾体抗炎药物为例，分析该类药物在2005～2007年的销售数量、销售金额及生产厂家风云榜。方法：采用药物分类累加的方法统计2005～2007年非甾体抗炎药的销售数量和金额排序，并对前10位药品销售数量和金额对比，及前10位厂家对比。结果：双氯芬酸稳居销售榜首，美洛昔康、布洛芬等药物位居其后。结论：新一代的非甾体抗炎药已经占据主要市场，各类药物各有特色，但是仍需注意其消化系统及心血管系统的不良反应。     

Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys.

Neurturin (NTN) is a potent survival factor for midbrain dopaminergic neurons. CERE-120, an adeno-associated virus type 2 (AAV2) vector encoding human NTN (AAV2-NTN), is currently being developed as a potential therapy for Parkinson's disease. This study examined the bioactivity and safety/tolerability of AAV2-NTN in the aged monkey model of nigrostriatal dopamine insufficiency. Aged rhesus monkeys received unilateral injections of AAV2-NTN into the caudate and putamen, with each animal therefore serving as its own control. Robust expression of NTN within the nigrostriatal system was observed 8 months postadministration. (18)F-fluorodopa imaging using positron emission tomography revealed statistically significant increases in (18)F-fluorodopa uptake in the injected striatum compared with the uninjected side at 4 and 8 months. In addition, at 8 months postadministration, a significant enhancement in tyrosine hydroxylase immunoreactive fibers and an increase in the number of tyrosine hydroxylase immunoreactive cells was observed in the AAV2-NTN injected striatum compared with the uninjected side. Robust activation of phosphorylated extracellular signal-regulated kinase immunoreactivity in the substantia nigra was also observed. Histopathological analyses revealed no adverse effects of AAV2-NTN in the brain. Collectively, these results are consistent with the neurotrophic effects of NTN on the dopaminergic nigrostriatal system and extend the growing body of evidence supporting the concept that AAV2-NTN may have therapeutic benefit for Parkinson's disease.     

氯胺酮对荷包牡丹碱诱导PC12细胞内Ca2+浓度波动方式的影响

目的研究氯胺酮对荷包牡丹碱诱导PCI2细胞内Ca^2＋浓度波动方式的影响。方法使用含25ng／LNGF的DMED培养基在多聚赖氨酸包被的培养皿中培养PCl2细胞；与终浓度10gmol／L的Ca^2＋指示剂Fluo-3 AM ester共孵育30min洗涤后，加入终浓度50gmol／L荷包牡丹碱；在激光共聚焦显微镜选定多个细胞分别测定荧光强度的变化；随后加入氯胺酮，记录细胞荧光强度的改变。在试验结束前依次加入Triton X-100和EGTA分别记录单个细胞最大荧光强度（Fmax）和最小荧光强度（Fmin），以计算细胞内Ca^2＋的相对强度。结果氯胺酮不改变荷包牡丹碱诱导PCl2细胞内Ca^2＋浓度波动的基线，但抑制细胞内Ca^2＋浓度升高的幅度（P〈0．05），缩短相邻波峰间的时间间隙（P〈0．05）。结论氯胺酮不仅改变荷包牡丹碱诱导PCl2细胞内Ca^2＋浓度升高的幅度，而且改变Ca^2＋浓度波动的周期。